Goldman Sachs (GS) spotlights Biohaven's BHV-1400 degrader as IgA nephropathy breakthrough

Degrader for autoimmune kidney disease becomes focal point for Goldman Sachs

Goldman Sachs is highlighting Biohaven’s BHV-1400 as a potentially differentiated therapeutic approach for IgA nephropathy (IgAN), placing the degrader at the centre of its initiation coverage. The bank notes early clinical data that suggest BHV-1400 may reduce pathogenic targets without producing the level of immunosuppression seen with some other agents, a profile that could support chronic administration in a disease for which long-term control is critical. Goldman estimates the U.S. market for IgAN at more than $40 billion, underscoring the clinical and commercial significance of a safer, durable treatment option.

The firm underscores the planned pivotal study for BHV-1400, which is scheduled to begin in early 2026, as the next major clinical milestone for Biohaven. Goldman’s analysts view the mechanism — targeted degradation of disease drivers — as potentially best-in-class if larger trials confirm the early signal for efficacy with a favourable safety and tolerability profile. Confirmation in a registrational trial would not only advance Biohaven’s lead nephrology asset but also validate a degrader strategy in the inflammation and immunology space.

Goldman also frames BHV-1400 as part of a broader shift in nephrology development toward therapies that balance robust disease control with long-term tolerability, particularly for autoimmune kidney diseases where lifetime treatment is common. A successful pivotal program could change prescribing patterns and spur interest in degraders across adjacent indications, altering competitive dynamics and development priorities among biotech firms focusing on chronic immune-mediated conditions.

Kv7 activator opakalim moves into pivotal testing for epilepsy

Goldman also highlights opakalim, Biohaven’s Kv7 channel activator for focal onset epilepsy, which is due to produce pivotal data in the second half of 2026. The bank points to roughly 1.8 million U.S. patients with focal seizures, about one-third of whom remain uncontrolled, and compares opakalim’s potential risk/benefit against competing Kv7 approaches such as Xene’s azetukalner.

Goldman frames Biohaven’s late-stage portfolio as a strategic asset for the company and the sector

Overall, Goldman views Biohaven’s mix of late-stage programs across inflammation & immunology, epilepsy and obesity as a substantive scientific and strategic platform. The firm identifies upcoming pivotal readouts in early and late 2026 as critical tests of that thesis and as potential inflection points for how the industry values degraders and next-generation ion-channel modulators.